Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein.

@article{Schwartz2006BevacizumabIU,
  title={Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein.},
  author={Jonathan D Schwartz and Myron Eliot Schwartz and Deborah Lehrer and Edmond Cohen and Max W. Sung and Mona Parikh Kinkhabwala and Abby B. Siegel and Shannon Holloway and Allyson J. Ocean and Scott S Wadler},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={4144}
}
4144 Background: HCC is a vascular tumor in which angiogenesis contributes to pathogenesis. VEGF-inhibition has not been previously attempted in cirrhosis or HCC. METHODS We enrolled patients with unresectable HCC to treatment with bevacizumab at 5 mg/kg or 10 mg/kg every 14 days to assess safety and preliminary efficacy. Inclusion criteria were BR < 3.0 mg/dl, transaminases 75K and PT within 4 seconds of normal. Additional criteria included no history of myocardial infarction, stroke, or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Management of hepatocellular carcinoma.

The Surgical clinics of North America • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…